Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Jeffrey Stock
Rbhs Robert Wood Johnson Medical School, Department: Neurology
Should you be removed from our database? Contact us at [email protected]. Read more below.
Signum Nutralogix Inc.
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
The PHS-funded research (a sub-award from Rutgers) involves in vitro biochemical analyses and cell based molecular experiments with the goal of developing a dietary supplement or medical food to slow the progression of Parkinson’s Disease. Signum Nutralogix has developed a dietary supplement based on caffeine derivatives which is currently marketed as an aid in strengthening brain health. There are also ongoing research initiatives looking at therapeutic agents to treat Alzheimer’s, Parkinson’s and other neurodegenerative diseases which is related to the research to be conducted under the NIH award.
Synergistic Neuroprotective Mechanisms of Coffee Components in Parkinson's Diseas
Coffee, which by far is the most widely and highly consumed herbal extract worldwide, has been linked to reduced risk of developing Parkinson's disease. While this effect has been attributed largely to caffeine, coffee has many more components than just caffeine. This project focuses on understanding the mechanisms by which certain coffee constituents protect brain cells. The ultimate goal of this work is to develop a dietary supplement(s) that would slow the progression or prevent the development of neurodegenerative disorders including Parkinson's disease.
Filed on March 19, 2015.
Tell us what you know about Jeffrey Stock's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.